Eli Lilly Lowers Insulin Costs as Coronavirus Crisis Deepens
Written by: Beyond Type 1 Editorial Team
1 minute read
April 7, 2020
Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak. “Enabling a $35-per-month insulin co-pay regardless of employment status will help many Americans in this difficult time,” said CEOs Aaron Kowalski and Thom Scher of non-profit organization JDRF-Beyond Type 1 Alliance.
Author
Beyond Type 1 Editorial Team
Beyond Type 1 is the largest diabetes org online, funding advocacy, education and cure research. Find industry news, inspirational stories and practical help. Join the 1M+ strong community and discover what it means to #LiveBeyond a diabetes diagnosis.
Related Resources
The American Diabetes Association's 2024 Scientific Sessions in Orlando assembled the top experts in diabetes...
Read more
Today Beyond Type 1, the leading diabetes nonprofit co-founded by Nick Jonas, announces a landmark...
Register here
After the Grammy-award winning singer met with the Fortune 500 exec, two main results emerged:...
Register here